Patents by Inventor Anja Molhart Hog
Anja Molhart Hog has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240026360Abstract: The present invention relates to antisense oligonucleotides that are capable of modulating expression of Tau in a target cell. The oligonucleotides hybridize to MAPT mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of Tauopathies, Alzheimer's disease, fronto-temporal dementia (FTD), FTDP-17, progressive supranuclear palsy (PSP), chronic traumatic encephalopathy (CTE), corticobasal ganglionic degeneration (CBD), epilepsy, Dravet syndrome, depression, seizure disorders and movement disorders.Type: ApplicationFiled: July 21, 2023Publication date: January 25, 2024Inventors: Peter HAGEDORN, Anja Mølhart HØG, Richard E. OLSON, Marianne L. JENSEN
-
Patent number: 11761951Abstract: The present disclosure provides methods of using a calcium oscillation assay and/or a sequence score calculation to identify a molecule that is safe for administration. The disclosure also includes a method of selecting or identifying a molecule having tolerable in vivo neurotoxicity using a calcium oscillation assay, a sequence score method, an in vivo tolerability assay, or any combination thereof.Type: GrantFiled: February 4, 2016Date of Patent: September 19, 2023Assignee: BRISTOL-MYERS SQUIBB COMPANYInventors: Richard E. Olson, Angela M. Cacace, Peter Hagedorn, Anja Mølhart Høg, Niels Fisker Nielsen, Dong LI, Jeffrey M. Brown, Stephen E. Mercer, Marianne Lerbech Jensen
-
Patent number: 11753640Abstract: The present invention relates to antisense oligonucleotides that are capable of modulating expression of Tau in a target cell. The oligonucleotides hybridize to MAPT mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of Tauopathies, Alzheimzer's disease, fronto-temporal dementia (FTD), FTDP-17, progressive supranuclear palsy (PSP), chronic traumatic encephalopathy (CTE), corticobasal ganglionic degeneration (CBD), epilepsy, Dravet syndrome, depression, seizure disorders and movement disorders.Type: GrantFiled: December 31, 2020Date of Patent: September 12, 2023Assignee: Hoffmann-La Roche Inc.Inventors: Peter Hagedorn, Anja Mølhart Høg, Richard E. Olson, Marianne L. Jensen
-
Publication number: 20220177884Abstract: The present invention relates to antisense oligonucleotides that are capable of modulating expression of Tau in a target cell. The oligonucleotides hybridize to MAPT mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of Tauopathies, Alzheimer's disease, fronto-temporal dementia (FTD), FTDP-17, progressive supranuclear palsy (PSP), chronic traumatic encephalopathy (CTE), corticobasal ganglionic degeneration (CBD), epilepsy, Dravet syndrome, depression, seizure disorders and movement disorders.Type: ApplicationFiled: January 21, 2022Publication date: June 9, 2022Applicant: HOFFMANN-LA ROCHE INC.Inventors: Peter HAGEDORN, Anja Mølhart HØG, Marianne L. JENSEN, Richard E. OLSON
-
Publication number: 20220143064Abstract: The present invention relates to oligomer compounds (oligomers), which target Tau mRNA in a cell, leading to reduced expression of Tau protein. Reduction of Tau protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.Type: ApplicationFiled: July 2, 2021Publication date: May 12, 2022Applicant: F. Hoffmann-La Roche AGInventors: Richard E. Olson, Angela M. Cacace, Peter Hagedorn, Anja Mølhart Høg, Marianne Lerbech Jensen, Niels Fisker Nielsen, Dong Li, Jeffrey M. Brown, Stephen E. Mercer
-
Patent number: 11279929Abstract: The present invention relates to antisense oligonucleotides that are capable of modulating expression of Tau in a target cell. The oligonucleotides hybridize to MAPT mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of Tauopathies, Alzheimzer's disease, fronto-temporal dementia (FTD), FTDP-17, progressive supranuclear palsy (PSP), chronic traumatic encephalopathy (CTE), corticobasal ganglionic degeneration (CBD), epilepsy, Dravet syndrome, depression, seizure disorders and movement disorders.Type: GrantFiled: July 3, 2019Date of Patent: March 22, 2022Assignee: Hoffmann-La Roche, Inc.Inventors: Peter Hagedorn, Anja Mølhart Høg, Marianne L. Jensen, Richard E. Olson
-
Patent number: 11077132Abstract: The present invention relates to oligomer compounds (oligomers), which target Tau mRNA in a cell, leading to reduced expression of Tau protein. Reduction of Tau protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.Type: GrantFiled: February 4, 2016Date of Patent: August 3, 2021Assignee: F. HOFFMANN-LA ROCHE AGInventors: Richard E. Olson, Angela M. Cacace, Peter Hagedorn, Anja Mølhart Høg, Marianne Lerbech Jensen, Niels Fisker Nielsen, Dong Li, Jeffrey M. Brown, Stephen E. Mercer
-
Publication number: 20210123054Abstract: The present invention relates to antisense oligonucleotides that are capable of modulating expression of Tau in a target cell. The oligonucleotides hybridize to MAPT mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of Tauopathies, Alzheimzer's disease, fronto-temporal dementia (FTD), FTDP-17, progressive supranuclear palsy (PSP), chronic traumatic encephalopathy (CTE), corticobasal ganglionic degeneration (CBD), epilepsy, Dravet syndrome, depression, seizure disorders and movement disorders.Type: ApplicationFiled: December 31, 2020Publication date: April 29, 2021Inventors: Peter HAGEDORN, Anja Mølhart HØG, Richard E. OLSON, Marianne L. JENSEN
-
Patent number: 10799523Abstract: The present invention relates to oligomer compounds (oligomers), which target Tau mRNA in a cell, leading to reduced expression of Tau protein. Reduction of Tau protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.Type: GrantFiled: February 4, 2016Date of Patent: October 13, 2020Assignee: F. HOFFMANN-LA ROCHE AGInventors: Richard E. Olson, Angela M. Cacace, Peter Hagedorn, Anja Mølhart Høg, Dong Li, Jeffrey M. Brown, Marianne Lerbech Jensen, Niels Fisker Nielsen, Stephen E. Mercer
-
Publication number: 20200010831Abstract: The present invention relates to antisense oligonucleotides that are capable of modulating expression of Tau in a target cell. The oligonucleotides hybridize to MAPT mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of Tauopathies, Alzheimzer's disease, fronto-temporal dementia (FTD), FTDP-17, progressive supranuclear palsy (PSP), chronic traumatic encephalopathy (CTE), corticobasal ganglionic degeneration (CBD), epilepsy, Dravet syndrome, depression, seizure disorders and movement disorders.Type: ApplicationFiled: July 3, 2019Publication date: January 9, 2020Applicant: Hoffmann-La Roche, Inc.Inventors: Peter HAGEDORN, Anja Mølhart HØG, Marianne L. JENSEN, Richard E. Olson
-
Publication number: 20190383797Abstract: The present disclosure provides methods of using a calcium oscillation assay and/or a sequence score calculation to identify a molecule that is safe for administration. The disclosure also includes a method of selecting or identifying a molecule having tolerable in vivo neurotoxicity using a calcium oscillation assay, a sequence score method, an in vivo tolerability assay, or any combination thereof.Type: ApplicationFiled: February 4, 2016Publication date: December 19, 2019Inventors: Richard E. OLSON, Angela M. CACACE, Peter HAGEDORN, Anja Mølhart HØG, Niels Fisker NIELSEN, Dong LI, Jeffrey M. BROWN, Stephen E. MERCER, Marianne Lerbech JENSEN
-
Publication number: 20180161356Abstract: The present invention relates to oligomer compounds (oligomers), which target Tau mRNA in a cell, leading to reduced expression of Tau protein. Reduction of Tau protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.Type: ApplicationFiled: February 4, 2016Publication date: June 14, 2018Inventors: Richard E. Olson, Angela M. Cacace, Peter Hagedorn, Anja Mølhart Høg, Marianne Lerbech Jensen, Niels Fisker Nielsen, Dong Li, Jeffrey M. Brown, Stephen E. Mercer
-
Publication number: 20180023081Abstract: The present invention relates to LNA oligomers having two flanks, wherein one or both flanks comprise alternating LNA and DNA nucleosides.Type: ApplicationFiled: February 4, 2016Publication date: January 25, 2018Inventors: Peter HAGEDORN, Richard E. OLSON, Anja Mølhart HØG, Marianne Lerbech JENSEN, Dong LI, Niels Fisker NIELSEN
-
Publication number: 20160237427Abstract: The present invention relates to oligomer compounds (oligomers), which target Tau mRNA in a cell, leading to reduced expression of Tau protein. Reduction of Tau protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.Type: ApplicationFiled: February 4, 2016Publication date: August 18, 2016Inventors: Richard E. OLSON, Angela M. CACACE, Peter HAGEDORN, Anja Mølhart HØG, Marianne Lerbech JENSEN, Niels Fisker NIELSEN, Dong LI, Jeffrey M. BROWN, Stephen E. MERCER
-
Patent number: 8785617Abstract: Oligonucleotides directed against the hypoxia-inducible factor-1? (HIF-1?) gene are provided for modulating the expression of HIF-1?. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the HIF-1?. Methods of using these compounds for modulation of HIF-1? expression and for the treatment of diseases associated with the hypoxia-inducible factor-1? are provided. Examples of diseases are cancer and pre-eclampsia. The oligonucleotides may be composed of deoxyribonucleosides, a nucleic acid analog, or Locked Nucleic Acid (LNA) or a combination thereof.Type: GrantFiled: December 21, 2012Date of Patent: July 22, 2014Assignee: Santaris Pharma A/SInventors: Charlotte Albaek Thrue, Anja Molhart Hog, Paul E. G. Kristjansen
-
Patent number: 8357670Abstract: Oligonucleotides directed against the hypoxia-inducible factor-1? (HIF-1?) gene are provided for modulating the expression of HIF-1?. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the HIF-1?. Methods of using these compounds for modulation of HIF-1? expression and for the treatment of diseases associated with the hypoxia-inducible factor-1? are provided. Examples of diseases are cancer and pre-eclampsia. The oligonucleotides may be composed of deoxyribonucleosides, a nucleic acid analogue, or Locked Nucleic Acid (LNA) or a combination thereof.Type: GrantFiled: May 22, 2012Date of Patent: January 22, 2013Assignees: Enzon Pharmaceuticals, Inc., Santaris Pharama A/SInventors: Charlotte Albaek Thrue, Anja Molhart Hog, Paul E. G. Kristjansen
-
Publication number: 20120270924Abstract: Oligonucleotides directed against the hypoxia-inducible factor-1? (HIF-1?) gene are provided for modulating the expression of HIF-1?. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the HIF-1?. Methods of using these compounds for modulation of HIF-1? expression and for the treatment of diseases associated with the hypoxia-inducible factor-1? are provided. Examples of diseases are cancer and pre-eclampsia. The oligonucleotides may be composed of deoxyribonucleosides, a nucleic acid analogue, or Locked Nucleic Acid (LNA) or a combination thereof.Type: ApplicationFiled: May 22, 2012Publication date: October 25, 2012Applicants: Santaris Pharma A/S, Enzon Pharmaceuticals. Inc.Inventors: Charlotte Albæk Thrue, Anja Mølhart Høg, Paul E.G. Kristjansen
-
Patent number: 8207140Abstract: Oligonucleotides directed against the hypoxia-inducible factor-1? (HIF-1?) gene are provided for modulating the expression of HIF-1?. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the HIF-1?. Methods of using these compounds for modulation of HIF-1? expression and for the treatment of diseases associated with the hypoxia-inducible factor-1? are provided. Examples of diseases are cancer and pre-eclampsia. The oligonucleotides may be composed of deoxyribonucleosides, a nucleic acid analogue, or Locked Nucleic Acid (LNA) or a combination thereof.Type: GrantFiled: October 27, 2010Date of Patent: June 26, 2012Assignees: Santaris Pharma A/S, Enzon Pharmaceuticals, Inc.Inventors: Charlotte Albaek Thrue, Anja Molhart Hog, Paul E. G. Kristjansen
-
Publication number: 20110224285Abstract: Oligonucleotides directed against the hypoxia-inducible factor-1? (HIF-1?) gene are provided for modulating the expression of HIF-1?. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the HIF-1?. Methods of using these compounds for modulation of HIF-1? expression and for the treatment of diseases associated with the hypoxia-inducible factor-1? are provided. Examples of diseases are cancer and pre-eclampsia. The oligonucleotides may be composed of deoxyribonucleosides, a nucleic acid analogue, or Locked Nucleic Acid (LNA) or a combination thereof.Type: ApplicationFiled: October 27, 2010Publication date: September 15, 2011Applicants: Enzon Pharmaceuticals, Inc., Santaris Pharma A/SInventors: Charlotte Albaek Thrue, Anja Molhart Høg, Paul E.G. Kristjansen
-
Publication number: 20110224281Abstract: The present invention relates to LNA oligomer compounds (oligomers), which target Hsp70 and mRNA in a cell, leading to reduced expression of Hsp70. Reduction of Hsp70 expression is beneficial for the treatment of certain medical disorders, such as hyperproliferative diseases, such as cancer.Type: ApplicationFiled: June 18, 2009Publication date: September 15, 2011Inventors: Anja Molhart Hog, Jens Bo Hansen